Clinical trial
Rasburicase in Tumor Lysis Syndrome
NCT00302653 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00302653 |
|---|---|
| Title | Rasburicase in Tumor Lysis Syndrome |
| Official title | Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome. |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hyperuricemia |
| Intervention type | Drug |
| Interventions | Rasburicase |
| Enrollment | 33 |
| Start date | Feb 1, 2006 |
| Primary completion | Nov 1, 2006 |
| First posted | Mar 14, 2006 |
| Last update posted | Sep 25, 2009 |
| Countries | Brazil |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: